At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 5 enrolled
Drug / intervention
C21 +1 moredrug
Likely dose
C21 1000 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Single-centre Study Investigating the Effect of C21 on Forearm Blood Flow in Healthy Male Subjects by Use of Strain-gauge Venous Occlusion Plethysmography
In Brief
A Phase 1 clinical trial evaluating C21 and Sodium Nitroprusside for Study Vasodilatory Effects of C21. Completed, enrolled 5 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the effect of C21 on forearm blood flow by use of strain-gauge venous occlusion plethysmography.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStudy Vasodilatory Effects of C21
CountriesSweden
CollaboratorsCTC Clinical Trial Consultants AB
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartApr 2022
Primary CompletionMay 2022
Study CompletionMay 2022
TodayJul 2026
First PostedMar 14, 2022
Enrollment StartApr 28, 2022
Primary CompletionMay 11, 2022
Study CompletionMay 18, 2022
TodayJul 2, 2026
Enrollment to primary: 13 daysPosted 4.3 years ago
Interventions
C21drug
C21 in ascending doses of 15, 50, 150, 500 and 1000 µg
Sodium Nitroprussidedrug
Ascending doses of 4, 8 and 16 µg sodium nitroprusside Positive control